Skip to main content

Dr. Michael S. Mcallister, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
24
In the NPI registry since
2006
Medicare patients seen, 2024
878

Licensed in Alabama since 2001, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2002Medical school: University of Alabama School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    AL license 24229 (first issued 2001; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
878
Services billed
254,954
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, levoleucovorin, not otherwise specified, 0.5 mg44,45013
Injection, aprepitant, 1 mg31,07065
Injection, pembrolizumab, 1 mg22,40026
Injection, granisetron, extended-release, 0.1 mg20,50056
Injection, oxaliplatin, 0.5 mg18,20013
Injection, denosumab, 1 mg13,92094
Injection, paclitaxel, 1 mg7,24013
Injection, ondansetron hydrochloride, per 1 mg5,204108
Injection, dexamethasone sodium phosphate, 1 mg4,662130
Injection, eflapegrastim-xnst, 0.1 mg4,48813

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 41 companies reported 138 payments worth $21,954 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$15,170
Food and Beverage$3,888
Travel and Lodging$2,896

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Mar 20, 2025Gilead Sciences, Inc.
Mar 20, 2025
Compensation for services other than consulting (speaking, faculty)
Trodelvy · ONC
Company’s description;4023012;GTF;10426707
$5,290
Jul 2, 2025Gilead Sciences, Inc.
Jul 2, 2025
Compensation for services other than consulting (speaking, faculty)
Trodelvy · ONC
Company’s description;4126911;AHM;10426707
$4,940
Oct 29, 2025Gilead Sciences, Inc.
Oct 29, 2025
Compensation for services other than consulting (speaking, faculty)
Trodelvy · ONC
Company’s description;4260223;AHM;10426707
$4,940
Oct 31, 2025Gilead Sciences, Inc.
Oct 31, 2025
Travel and Lodging
Trodelvy · ONC · travel to Mobile, AL · in-kind
Company’s description;4328010;AHM;10426707
$1,396
Feb 11, 2025Gilead Sciences, Inc.
Feb 11, 2025
Travel and Lodging
Trodelvy · ONC · travel to Dallas, TX
Company’s description;4022885;GTF;10426707
$668
Jun 10, 2025Gilead Sciences, Inc.
Jun 10, 2025
Travel and Lodging
Trodelvy · ONC · travel to Biloxi, MS · in-kind
Company’s description;4098820;AHM;10426707
$354
Feb 19, 2025Gilead Sciences, Inc.
Feb 19, 2025
Travel and Lodging
Trodelvy · ONC · travel to Dallas, TX · in-kind
Company’s description;4022656;GTF;10426707
$293
May 15, 2025Gilead Sciences, Inc.
May 15, 2025
Travel and Lodging
Trodelvy · ONC · travel to Biloxi, MS · in-kind
Company’s description;4123437;AHM;10426707
$167
Feb 22, 2025Gilead Sciences, Inc.
Feb 22, 2025
Travel and Lodging
Trodelvy · ONC · travel to Dallas, TX
Company’s description;4022932;GTF;10426707
$18.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Alabama →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $149,755 in research payments for these studies, mostly to the institutions running them.

  • CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase In…
    AstraZeneca UK Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Dothan

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 1, 2016), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1720170053. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.